';
Substance Use Disorder

The Moral Matters podcast recently discussed “Lobbying for Good” with Richard Edley, PhD, who is a psychologist and current President/CEO of RCPA, an advocacy and lobbying organization in Pennsylvania that supports community health and human services organizations. He shares his journey to this career, and why we should all learn more about how lobbyists — and even political action committees — might be acting on our behalf. Listen to the podcast here.

Photo by Markus Winkler from Pexels

On May 1, Beacon Health Options of Pennsylvania, Inc., the behavioral health Medicaid managed care organization serving members in Western Pennsylvania, is becoming Carelon Health of Pennsylvania, Inc.

In June 2022, Beacon’s parent company Elevance Health announced the launch of Carelon, a new healthcare services brand. The name Carelon is derived from the word “care” and suffix “-lon,” which means full and complete. Beacon is joining with other businesses across the nation under the Carelon brand to provide ongoing healthcare services to support whole-person health.

Provider contracts, reimbursement, policies, and points of contact will all remain the same. All existing phone numbers, emails, websites, and portals will redirect to the Carelon-branded locations with no action required from providers.

Providers with questions can call 877-615-8503.

Today, the Pennsylvania Department of Drug and Alcohol Programs (DDAP) issued Licensing Alert 01-2023 to detail continued expansion of the availability of take-home methadone through the ongoing suspension of 28 Pa. Code § 715.16(e).

On Feb. 9, 2023, the US Department of Health and Human Services announced the final renewal of the federal public health emergency (PHE) declaration. The PHE will not be renewed when it expires on May 11, 2023. Both the federal and Pennsylvania Department of Drug and Alcohol Programs’ (DDAP) expansions of the availability of take-home methadone will remain in place until May 11, 2024. DDAP will keep the field aware of developments at the federal level that could extend flexibilities beyond May 2024. Read the full alert and background information on the regulatory suspension.

With the passage of the 2023 federal omnibus bill, which included the Mainstreaming Addiction Treatment Act, Congress eliminated the “DATA-Waiver Program.” The DATA-waiver is commonly referred to as the X-waiver.

Now, the requirement to have an X-waiver from the Drug Enforcement Agency (DEA) and Substance Abuse and Mental Health Services Administration (SAMSHA) to prescribe buprenorphine, a Schedule III narcotic, for opioid use disorder (OUD) has been removed. Any prescriber with a general DEA license can prescribe the medication.

DDAP is reminding DEA registrants of the following:

  • A DATA-Waiver registration is no longer required to treat patients with buprenorphine for OUD.
  • Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
  • There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
  • In Pennsylvania, no current state laws or regulations prohibit practitioners from adopting this change.

Separately, the Act also introduced new training requirements for all prescribers. These requirements will go into effect on June 21, 2023. The DEA and SAMHSA are actively working to provide further guidance and DEA will follow up with additional information on these requirements. Please contact the DEA’s Diversion Control Division Policy Section for additional guidance.

The sustained funding of community-based mental health services, such as community residential programs, family-based support, outpatient care, and crisis intervention, are critical to the wellbeing of our constituents and our communities. Funding levels for county mental health services have direct impacts on whether these important community and family supports will be available. Yet for too many years, state funding for mental health services has lagged far behind its needs. Counties find themselves advocating for the prevention of funds being cut instead of achieving the increases that are needed to catch up from years of underfunding.

This year, RCPA and other system stakeholders once again teamed with the County Commissioner Association of Pennsylvania (CCAP) through the Mental Health Safety Net Coalition. The mission and vision of this campaign continues to promote awareness of the critical funding needs of mental health services for vulnerable Pennsylvanians. As RCPA and the Mental Health Safety Net Coalition continue our efforts, we ask our members, stakeholders, and partners to join us in this collaborative effort by engaging with your legislators. “County mental health services provide a critical piece to the public safety net for people in need,” notes Richard S. Edley, PhD, President and CEO of RCPA. “The system sustained cuts over a decade ago with little relief since then. It is time to restore those dollars and further enhance the system. Not only will it provide critical funding for the individuals receiving services, but there are positive benefits — both financially and clinically — to the entire community.”

The Coalition welcomes the many new partners for this 2023–24 initiative, as the time to act is now for engaging with your representative. Local communities and providers have come together to sustain the safety net and serve those who need it most. The reality is that the demand for service far outweighs capacity and rate structures to serve this population.

View our first of many communications that will go out on behalf of the Coalition as an open call to the PA General Assembly and stakeholders. This will provide you with strategic talking points for our outreach. If you have additional questions or would like to join the Mental Health Safety Net Coalition, please contact RCPA Policy Director Jim Sharp.